Activation of CD8 T Cells Predicts Progression of HIV Infection in Women Coinfected with Hepatitis C Virus

Activation of CD8 T Cells Predicts Progression of HIV Infection in Women Coinfected with Hepatitis C Virus

"HCV coinfection was associated with increased CD8 activation. Finally, our most important finding was the statistically significant association between the level of activated CD8 T cells and incident AIDS among HCV‐positive viremic women. HCV‐positive viremic women with >43% activated CD8 T cells had an almost 3‐fold increased risk of AIDS‐defining conditions and/or AIDS‐related deaths compared with HCV‐positive viremic women with <26% activated CD8 T cells. This was not found for HCV‐negative women"........Ongoing antigen‐driven activation of CD8 T cells ultimately leads to CD8 T cell exhaustion and replicative senescence, which lead to inability to fight opportunistic pathogens....... factors that drive immune activation may increase the available targets for further viral replication. Finally, HCV infection may impair T cell maturation more globally to a more immature primed activated phenotype and also may impair responses to Toll‐like receptors, suggesting that both the innate and adaptive arms are affected [24, 39].....Animal studies have suggested that immune activation, rather than viral load, is linked to HIV disease progression [8].....The 592 women with immune activation data were slightly older (mean age, 37.4 vs 35.5 years); were more likely African American or Hispanic (82.5% vs 77.5%), injection drug users (53% vs 27%), and smokers (58% vs 49%); and had higher CD4 cell counts (mean, 439 vs 403 cells/μL) and CD8 cell counts (mean, 964 vs 867 cells/μL) than women without these data (data not shown)."


The Journal of Infectious Diseases March 15 2010

"...HCV‐positive viremic women had a statistically significantly higher percentage of activated CD8 T cells (p<.001)...

...HCV‐positive viremic women with HIV coinfection who have high levels of T cell activation may have increased risk of AIDS...

....In adjusted generalized estimating equation models, percentage of CD8+CD38+DR+ T cells was statistically significantly positively associated with HCV status (p=.04). Other independent correlates of CD8 activation included HIV RNA level and ART.......HCV‐positive viremic women were more likely to have bacterial pneumonia (20% vs 13%; p=.002 ), dementia and/or encephalopathy (11% vs 7%; p=.02), and wasting syndrome (12% vs 8%; p=.03) than were HCV‐negative women.....HCV‐positive viremic women were more likely to develop AIDS with an HCV RNA level of >2.3 million IU/mL.....and were more likely to die an AIDS‐related death with an HCV RNA level of >3.98 million IU/mL...

....Immune activation has been closely linked to HIV disease progression [1, 4, 5, 34–36], but to our knowledge this association has not previously been reported in the setting of HCV coinfection....

.....our findings from this large cohort study, which included 1307 women, are notable: HCV coinfection was associated with increased CD8 activation. Finally, our most important finding was the statistically significant association between the level of activated CD8 T cells and incident AIDS among HCV‐positive viremic women. HCV‐positive viremic women with >43% activated CD8 T cells had an almost 3‐fold increased risk of AIDS‐defining conditions and/or AIDS‐related deaths compared with HCV‐positive viremic women with <26% activated CD8 T cells. This was not found for HCV‐negative women.....data suggest that the increased risk of HIV disease progression among HCV‐coinfected women with high levels of CD8 activation may be due to immune dysfunction....

....We determined that (1) HCV viremia is associated with AIDS outcome, independent of injection drug use, HIV RNA level, CD4 cell count, and ART (Table 2); (2) HCV viremia is associated with CD4 and CD8 activation, independent of HIV RNA level (Table 3); and (3) high levels of CD8 activation are associated with AIDS in HCV‐positive viremic women but not in HCV‐negative women.....

.....In conclusion, our study demonstrates that HIV‐coinfected HCV‐positive viremic women are at increased risk for AIDS‐defining conditions compared with HCV‐negative women, possibly because of high levels of activation of T cells, especially CD8 T cells, which indicates increased immune dysregulation in this population of women. Lower levels of activation of both CD8 and CD4 T cells and activation of CD8 T cells expressing only HLA‐DR is protective against AIDS. Further study is needed to understand better the pathogenesis of T cell activation, especially of CD8 T cells in relation to HIV disease. HCV‐positive viremic women may benefit from treatment of HIV and HCV infection to prevent significant immunologic changes and improve long‐term outcome. Assessing CD4 and CD8 T cell activation could help clinicians evaluate their patients’ risk of developing AIDS.....

.....CD8+CD38−DR+ T cells appear to have high proliferative capacity and cytotoxic activity upon antigenic stimulation. Our study results suggest further research is needed to better understand the path of CD8 activation, especially the protective effect of HLA‐DR expression.....

...HCV viremic women were more likely to report wasting syndrome, bacterial pneumonia, and encephalopathy at the end of follow‐up....

.....Our multivariate models showed that the causal pathway between T cell activation and HIV disease progression cannot be completely explained by HIV or HCV viral load, and other mediators of CD8 activation may be involved in increasing AIDS risk. This may be because substantial immune activation occurs in tissues such as the liver, and viral load may not reflect the extent of the activation....Whether the liver plays a role in amplifying or modulating this activation, especially with prior HCV infection, is unknown, but a recent study found evidence of increased microbial translocation among HCV‐positive individuals with cirrhosis......

......This finding suggests that HCV‐positive viremic women may be at continued risk for certain AIDS‐defining conditions and further supports the importance of treatment in this group. The pathogenesis of these findings may be HCV‐related infection of the central nervous system and/or progressive liver disease including cirrhosis. Bacterial pneumonia is increased among HIV‐infected individuals, especially injection drug users [44, 45], and cirrhosis may play a role in some who are coinfected with HCV. However, continued immune activation is also associated with encephalopathy, and some studies have suggested that microbial translocation related to gut‐associated immunodeficiency may be a contributing factor [43, 46–48]. Furthermore, wasting syndrome may be a manifestation of chronic and severe gut‐associated immunodeficiency that may be exacerbated by progressive HCV disease and/or alcohol use.......

.......In vitro studies have shown that CD8 T cells have a lower threshold for activation and proliferation compared with CD4 T cells [37]. Ongoing antigen‐driven activation of CD8 T cells ultimately leads to CD8 T cell exhaustion and replicative senescence, which lead to inability to fight opportunistic pathogens [4]. The factors that influence T cell activation among the women included in our study are most likely multifactorial and may be a direct consequence of activation in the liver or may be related to extrahepatic replication of HCV [38]. Alternatively, host‐specific factors (eg, cytokines) may drive persistent T cell activation. Furthermore, factors that drive immune activation may increase the available targets for further viral replication. Finally, HCV infection may impair T cell maturation more globally to a more immature primed activated phenotype and also may impair responses to Toll‐like receptors, suggesting that both the innate and adaptive arms are affected [24, 39]."

Andrea Kovacs,1 Roksana Karim,1,2 Wendy J. Mack,2 Jiaao Xu,1 Zhi Chen,1 Eva Operskalski,1 Toni Frederick,1 Alan Landay,4 John Voris,4 La Shonda Spencer,1 Mary A. Young,5 Phyllis C. Tien,3 Michael Augenbraun,6 Howard D. Strickler,7 and Lena Al‐Harthi3


1Maternal, Child, and Adolescent Center for Infectious Diseases and Virology and 2Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, and 3Department of Medicine, University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, California; 4Department of Immunology and Microbiology, Rush University Medical Center, Chicago, Illinois; 5Division of Infectious Diseases, Georgetown University, Washington, D.C.; 6Department of Medicine, State University of New York Downstate College of Medicine, Brooklyn, and 7Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York

ABSTRACT

Background. Because activation of T cells is associated with human immunodeficiency virus (HIV) pathogenesis, CD4 and CD8 activation levels in patients coinfected with HIV and hepatitis C virus (HCV) may explain conflicting reports regarding effects of HCV on HIV disease progression.


Methods. Kaplan‐Meier and multivariate Cox regression models were used to study the risk of incident clinical AIDS and AIDS‐related deaths among 813 HCV‐negative women with HIV infection, 87 HCV‐positive nonviremic women with HIV coinfection, and 407 HCV‐positive viremic women with HIV coinfection (median follow‐up time, 5.2 years). For 592 women, the percentages of activated CD4 and CD8 T cells expressing HLA‐DR (DR) and/or CD38 were evaluated.


Results. HCV‐positive viremic women had a statistically significantly higher percentage of activated CD8 T cells (p<.001) and a statistically significantly higher incidence of AIDS compared with HCV‐negative women (p<.001 [log‐rank test]). The AIDS risk was greater among HCV‐positive viremic women in the highest tertile compared with the lowest tertile (>43% vs <26%) of CD8+CD38+DR+ T cells (hazard ratio, 2.94 [95% confidence interval, 1.50–5.77]; p=.001). This difference was not observed in the HCV‐negative women (hazard ratio, 1.87 [95% confidence interval, 0.80–4.35]; p=.16). In contrast, CD4 activation predicted AIDS in both groups similarly. Increased percentages of CD8+CD38−DR+, CD4+CD38−DR−, and CD8+CD38−DR− T cells were associated with a >60% decreased risk of AIDS for HCV‐positive viremic women and HCV‐negative women.


Conclusion. HCV‐positive viremic women with HIV coinfection who have high levels of T cell activation may have increased risk of AIDS. Earlier treatment of HIV and HCV infection may be beneficial.

Persistent generalized immune activation is a hallmark of human immunodeficiency virus (HIV) infection and is associated with CD4 cell count and HIV RNA level [1–7]. Activation of T cells accelerates their maturation and is associated with decreased CD4 level, increased HIV replication, more rapid HIV disease progression, and a decreased amount of CD4 gain following highly active antiretroviral therapy. Animal studies have suggested that immune activation, rather than viral load, is linked to HIV disease progression [8].


Worldwide, many HIV‐infected individuals are coinfected with hepatitis C virus (HCV). However, studies of the effect of HCV on HIV disease progression have been conflicting [9–19]. In contrast, all studies find liver disease to be accelerated in HIV‐coinfected patients compared with patients singly infected with HCV [20–22]. Determining the association between HCV and HIV is critical for clinical management of both infections in coinfected patients. We assessed the effect of HIV and HCV on HIV disease progression in a prospective cohort of women, and we determined the percentages of CD4 and CD8 T cells that expressed the cell surface markers HLA‐DR (DR) and/or CD38 as measures of immune activation. We hypothesized that the combined effects of these 2 viruses would be increased immune activation and higher likelihood of HIV disease progression.

Results


Demographic and baseline clinical characteristics of study participants.Among the 1307 women included in the study, there were 813 HCV‐negative women (62%), 87 HCV‐positive nonviremic women (7%), and 407 HCV‐positive viremic women (31%). Among the 260 HCV‐positive viremic women for whom HCV genotype was determined, 210 (80%) were infected with genotype 1. HCV‐positive women were older and more likely to be injection drug users than HCV‐negative women (Table 1). Number of sexual partners and CD4 and CD8 cell counts were similar among the groups. The overall prevalence of injection drug use during the follow‐up period was 0.4% (range, 0%–1%) in HCV‐negative women, 10.5% (range, 0%–21%) in HCV‐positive nonviremic women, and 12.7% (range, 6%–26%) in HCV‐positive viremic women (p<.001 [χ2 test]; data not shown). Although anti‐HCV therapy was not generally given during the period of this study, 19 of 1307 women received interferon, the majority after the 10th visit. Among these 19 women, there were 14 HCV‐positive viremic women, 1 HCV‐positive nonviremic woman, and 4 HCV‐negative women. None of these women received ribavirin.

The 592 women with immune activation data were slightly older (mean age, 37.4 vs 35.5 years); were more likely African American or Hispanic (82.5% vs 77.5%), injection drug users (53% vs 27%), and smokers (58% vs 49%); and had higher CD4 cell counts (mean, 439 vs 403 cells/μL) and CD8 cell counts (mean, 964 vs 867 cells/μL) than women without these data (data not shown).


Disease progression and HCV.Among the 1307 women who were AIDS free at baseline, 495 developed AIDS, including 162 women who died an AIDS‐related death during 10 years of follow‐up. Although at the time of first AIDS diagnosis there were no statistically significant differences in reported individual AIDS‐defining conditions between HCV‐negative women and HCV‐positive women, by the end of follow‐up HCV‐positive viremic women were more likely to have bacterial pneumonia (20% vs 13%; ), dementia and/or encephalopathy (11% vs 7%; ), and wasting syndrome (12% vs 8%; ) than were HCV‐negative women. By the end of follow‐up, HCV‐positive viremic women were also more likely to have tuberculosis than were HCV‐negative women; however, the difference was borderline statistically significant (6% vs 4%; ). HCV‐positive viremic women were less likely to have any cancer (5% vs 8%; ) and toxoplasmosis (0.6% vs 2%; ) than were HCV‐negative women.


Kaplan‐Meier analyses showed that HCV‐positive viremic women were more likely to develop AIDS with an HCV RNA level of >2.3 million IU/mL (Figure 3A) and were more likely to die an AIDS‐related death with an HCV RNA level of >3.98 million IU/mL (Figure 3B) than were women in the other groups ( and , respectively [log‐rank test]). Among women who never had a CD4 cell count of <200 cells/μL, HCV‐positive women (regardless of HCV RNA status) were more likely to develop AIDS than were HCV‐negative women (Figure 3C), with rates at 1, 3, and 5 years after study entry of 13% vs 7%, 26% vs 16%, and 33% vs 21%, respectively ( ).

Disease progression and HCV.
Among the 1307 women who were AIDS free at baseline, 495 developed AIDS, including 162 women who died an AIDS‐related death during 10 years of follow‐up. Although at the time of first AIDS diagnosis there were no statistically significant differences in reported individual AIDS‐defining conditions between HCV‐negative women and HCV‐positive women, by the end of follow‐up HCV‐positive viremic women were more likely to have bacterial pneumonia (20% vs 13%; p=.002), dementia and/or encephalopathy (11% vs 7%; p=.02), and wasting syndrome (12% vs 8%; p=.03) than were HCV‐negative women. By the end of follow‐up, HCV‐positive viremic women were also more likely to have tuberculosis than were HCV‐negative women; however, the difference was borderline statistically significant (6% vs 4%; p=.06). HCV‐positive viremic women were less likely to have any cancer (5% vs 8%; ) and toxoplasmosis (0.6% vs 2%; ) than were HCV‐negative women.


Kaplan‐Meier analyses showed that HCV‐positive viremic women were more likely to develop AIDS with an HCV RNA level of >2.3 million IU/mL (Figure 3A) and were more likely to die an AIDS‐related death with an HCV RNA level of >3.98 million IU/mL (Figure 3B) than were women in the other groups (p<.001 and p=.03, respectively [log‐rank test]). Among women who never had a CD4 cell count of <200 cells/μL, HCV‐positive women (regardless of HCV RNA status) were more likely to develop AIDS than were HCV‐negative women (Figure 3C), with rates at 1, 3, and 5 years after study entry of 13% vs 7%, 26% vs 16%, and 33% vs 21%, respectively (p<.001).

After adjusting for age, race, smoking, and ART, we found HCV status, injection drug use, CD4 cell count, and HIV plasma RNA level to be independent risk factors for AIDS‐defining conditions in the Cox model (Table 2). Compared with women who never had a CD4 cell count of <200 cells/μL, women with a current and previous CD4 cell count of <200 cells/μL had a 3‐fold increased risk of AIDS and AIDS‐related death (HR, 3.48 [95% CI, 2.77–4.36]). This was confirmed in a separate model that assessed visit‐specific CD4 cell counts of <200 vs >500 cells/μL (HR, 3.00 [95% CI, 2.26–4.00]; data not shown). Alcohol use, prophylactic antibiotic use, and aspartate to platelet ratio index were not statistically significant predictors of AIDS, and their inclusion in multivariate models did not alter HR estimates for injection drug use, HCV status, CD4 cell count, and HIV RNA levels. Among ART‐naive women, HCV‐positive viremic women had a 2‐fold higher risk of AIDS compared with HCV‐negative women (data not shown).

Association between level of immune activation and HCV status.
HCV status was statistically significantly correlated with CD8+CD38+DR+ and CD4+CD38+DR+ T cell levels in univariate analyses (Table 3). In adjusted generalized estimating equation models, percentage of CD8+CD38+DR+ T cells was statistically significantly positively associated with HCV status (p=.04). Other independent correlates of CD8 activation included HIV RNA level and ART. For CD4+CD38+DR+ T cells, there was no statistically significant positive trend overall by HCV status. However, after the HCV‐negative group was removed from the analysis, the trend was statistically significant among HCV‐positive women (p=.02).

Immune activation and risk of AIDS.
Among the 592 women with immune activation data, AIDS risk was statistically significantly increased among women in the highest tertile of CD8+CD38+DR+ T cells compared with women in the lowest tertile of CD8+CD38+DR+ T cells, and among women in the highest tertile of CD4+CD38+DR+ T cells compared with women in the lowest tertile of CD4+CD38+DR+ T cells (Table 4). In contrast, higher percentages of CD8+CD38−DR−, CD8+CD38−DR+, and CD4+CD38−DR− T cells were statistically significantly protective against AIDS. When we adjusted for HIV RNA level, these associations remained unchanged. However, after adjusting for CD4 cell count or CD4 cell count and HIV RNA level, HRs remained statistically significant only for CD8+CD38−DR+ and CD4+CD38+DR+ T cells. Of note, HRs for each HCV RNA level were not statistically significant in any immune marker models: in model 1 for CD8+CD38+DR+ T cells, the HR was 0.94 (95% CI, 0.48–1.82) for HCV‐positive nonviremic women and 0.88 (95% CI, 0.45–1.73), 1.67 (95% CI, 0.62–2.20), 1.14 (95% CI, 0.61–2.17), and 1.14 (95% CI, 0.60–2.17) for HCV‐positive viremic women with RNA levels of 983,000, 983,001–2,395,000, 2,395,001–3,980,000, and >3,980,001 IU/mL, respectively.

Immune activation and risk of AIDS in HCV‐negative and HCV‐positive viremic women.
Stratified analyses showed that among HCV‐positive viremic women (n=278), AIDS risk was statistically significantly increased with higher percentages of CD8+CD38+DR+ and CD4+CD38+DR+ T cells (Table 4). However, for HCV‐negative women, percentage of CD8+CD38+DR+ T cells was not statistically significantly associated with AIDS. Conversely, higher percentages of CD4+CD38−DR−, CD8+CD38−DR−, and CD8+CD38−DR+ T cells were associated with decreased AIDS risk for both groups. After additional adjustments for HIV RNA level, CD4 cell count, or both, risk was altered but remained statistically significant for CD8+CD38−DR+ and CD4+CD38+DR+ T cells and was borderline statistically significant for CD8+CD38+DR+ T cells only among HCV‐positive viremic women. For HCV‐negative women (n=242), HRs remained statistically significant only for CD8+CD38−DR+ and CD4+CD38+DR+ T cells after adjusting for HIV RNA level (Table 4). HRs were not statistically significantly different between HCV‐positive viremic women and HCV‐negative women (p>.50 for all interactions).



Discussion


HIV‐positive patients with chronic active or reactivating viral coinfections (eg, cytomegalovirus or herpes simplex virus coinfections) have higher plasma HIV RNA levels, lower T cell counts, and greater progression to AIDS compared with HIV‐positive patients without evidence of infection/reactivation [31, 32]. For HCV coinfection, however, there have been conflicting reports [10–19]. Consequently, our findings from this large cohort study, which included 1307 women, are notable. First, women with high baseline HCV RNA levels have an increased risk of AIDS, independent of CD4 cell count and HIV RNA level. Second, there was an almost 2‐fold increased probability of developing AIDS for HCV‐positive women compared with HCV‐negative women who never had a CD4 cell count of <200 cells/μL and for women who remained ART naive. Third, HCV coinfection was associated with increased CD8 activation. Finally, our most important finding was the statistically significant association between the level of activated CD8 T cells and incident AIDS among HCV‐positive viremic women. HCV‐positive viremic women with >43% activated CD8 T cells had an almost 3‐fold increased risk of AIDS‐defining conditions and/or AIDS‐related deaths compared with HCV‐positive viremic women with <26% activated CD8 T cells. This was not found for HCV‐negative women. In contrast, high levels of CD4 activation similarly predicted AIDS in both groups of women. These data suggest that the increased risk of HIV disease progression among HCV‐coinfected women with high levels of CD8 activation may be due to immune dysfunction. Importantly, we also showed that women with high percentages of CD8+CD38−DR+ and CD4+CD38−DR− or CD8+CD38−DR− T cells had a 50%–70% decreased AIDS risk, which suggests better immunity among this group of women.


To our knowledge, the Swiss HIV Cohort Study [17] was the first large study to demonstrate that HCV accelerated HIV disease independent of injection drug use. Other studies found no effect of HCV on HIV disease progression, although recent studies have reported increased risk [9–19]. Our study, in which only 10%–20% of the participants were active injection drug users during follow‐up, demonstrates an increased risk of an AIDS‐defining condition with increasing HCV RNA level. Furthermore, our study assessed outcome from the time of study entry to the time of an AIDS‐defining condition adjusting for ART in time‐dependent Cox models, whereas some studies limited outcome from initiation of highly active ART or excluded women with CD4 cell counts of <200 cells/μL at baseline, neither of which was done in our study. Although the effect of HCV genotype on immune activation is unknown, most women in our study were infected with genotype 1, which is associated with higher HCV RNA levels [33]. In our study, higher HCV RNA levels correlate with higher levels of immune activation. Differences in genotype or in rates of active injection drug use may explain differences between the results of our study and those in previous reports [19].


Immune activation has been closely linked to HIV disease progression [1, 4, 5, 34–36], but to our knowledge this association has not previously been reported in the setting of HCV coinfection. Our finding of increased incidence of AIDS‐defining conditions in relation to high levels of immune activation suggests that there is impaired T cell function in HCV‐positive viremic women that may potentially put them at higher risk of HIV disease progression compared with HCV‐negative women.


There are a number of factors that could potentially influence immune activation and in turn pathogenesis of HIV disease, including age, race, gender, injection drugs, use of highly active ART and antibiotic prophylaxis, smoking, alcohol, HCV genotype, and extent of liver damage. We evaluated for each of these in univariate models and then in multivariate models when appropriate.


In vitro studies have shown that CD8 T cells have a lower threshold for activation and proliferation compared with CD4 T cells [37]. Ongoing antigen‐driven activation of CD8 T cells ultimately leads to CD8 T cell exhaustion and replicative senescence, which lead to inability to fight opportunistic pathogens [4]. The factors that influence T cell activation among the women included in our study are most likely multifactorial and may be a direct consequence of activation in the liver or may be related to extrahepatic replication of HCV [38]. Alternatively, host‐specific factors (eg, cytokines) may drive persistent T cell activation. Furthermore, factors that drive immune activation may increase the available targets for further viral replication. Finally, HCV infection may impair T cell maturation more globally to a more immature primed activated phenotype and also may impair responses to Toll‐like receptors, suggesting that both the innate and adaptive arms are affected [24, 39].


Our study systematically evaluated the association between HCV viremia, immune activation, and AIDS outcome. We determined that (1) HCV viremia is associated with AIDS outcome, independent of injection drug use, HIV RNA level, CD4 cell count, and ART (Table 2); (2) HCV viremia is associated with CD4 and CD8 activation, independent of HIV RNA level (Table 3); and (3) high levels of CD8 activation are associated with AIDS in HCV‐positive viremic women but not in HCV‐negative women. Our multivariate models showed that the causal pathway between T cell activation and HIV disease progression cannot be completely explained by HIV or HCV viral load, and other mediators of CD8 activation may be involved in increasing AIDS risk. This may be because substantial immune activation occurs in tissues such as the liver, and viral load may not reflect the extent of the activation. For instance, recently there has been evidence that the gastrointestinal tract is a site for activation of T cells as a result of microbial translocation. Gut‐associated T cell depletion may also have a significant effect on HIV pathogenesis [8, 40–42]. From the intestines, T cells and microbial antigens circulate directly through the liver, where activation may continue. Whether the liver plays a role in amplifying or modulating this activation, especially with prior HCV infection, is unknown, but a recent study found evidence of increased microbial translocation among HCV‐positive individuals with cirrhosis [43]. In our study, liver biopsy data were unavailable. However, we did evaluate for liver disease by use of the aspartate to platelet ratio index [30] and found no statistically significant correlation with AIDS risk. Furthermore, we found no association between alcohol use and AIDS outcome. On the other hand, although at the time of AIDS diagnosis there were no statistically significant differences in individual AIDS‐defining conditions noted between HCV‐negative women and HCV‐positive women, HCV viremic women were more likely to report wasting syndrome, bacterial pneumonia, and encephalopathy at the end of follow‐up. This finding suggests that HCV‐positive viremic women may be at continued risk for certain AIDS‐defining conditions and further supports the importance of treatment in this group. The pathogenesis of these findings may be HCV‐related infection of the central nervous system and/or progressive liver disease including cirrhosis. Bacterial pneumonia is increased among HIV‐infected individuals, especially injection drug users [44, 45], and cirrhosis may play a role in some who are coinfected with HCV. However, continued immune activation is also associated with encephalopathy, and some studies have suggested that microbial translocation related to gut‐associated immunodeficiency may be a contributing factor [43, 46–48]. Furthermore, wasting syndrome may be a manifestation of chronic and severe gut‐associated immunodeficiency that may be exacerbated by progressive HCV disease and/or alcohol use.


Our study results confirm those of previous studies that the presence of HLA‐DR on CD8 T cells without CD38 expression appears to be protective [36, 49]. This is consistent with reports showing that elite controllers have higher percentages of HIV‐specific and global CD8+CD38−DR+ T cells [49]. CD8+CD38−DR+ T cells appear to have high proliferative capacity and cytotoxic activity upon antigenic stimulation. Our study results suggest further research is needed to better understand the path of CD8 activation, especially the protective effect of HLA‐DR expression.


Although our study is unique, it has limitations. We did not have information on the timing of HIV or HCV infection. Furthermore, HCV‐positive women and HCV‐negative women may be different because of differing routes of HIV infection (injection drug use vs sexual). Immune activation markers were measured for only a subset of the study population [7, 24, 25], and not all phenotypic markers were measured at the same time. Nevertheless, our results confirmed previous observations by other investigators [1, 6, 36]. Finally, we evaluated HCV RNA levels only at baseline because not all women underwent multiple measures. We assumed that HCV RNA levels would not change substantially in women who were not treated for HCV infection, on the basis of published studies that found that even with initiation and discontinuation of highly active ART there is only a 0.43–0.59 log change in HCV viral load [50]; such small changes would not affect our findings.


In conclusion, our study demonstrates that HIV‐coinfected HCV‐positive viremic women are at increased risk for AIDS‐defining conditions compared with HCV‐negative women, possibly because of high levels of activation of T cells, especially CD8 T cells, which indicates increased immune dysregulation in this population of women. Lower levels of activation of both CD8 and CD4 T cells and activation of CD8 T cells expressing only HLA‐DR is protective against AIDS. Further study is needed to understand better the pathogenesis of T cell activation, especially of CD8 T cells in relation to HIV disease. HCV‐positive viremic women may benefit from treatment of HIV and HCV infection to prevent significant immunologic changes and improve long‐term outcome. Assessing CD4 and CD8 T cell activation could help clinicians evaluate their patients’ risk of developing AIDS.



Acknowledgment


We thank the participants of this study. Data in this manuscript were collected by the Women's Interagency HIV Study (WIHS) Collaborative Study Group, with centers (Principal Investigators) located at New York City/Bronx Consortium (Kathryn Anastos); Brooklyn, NY (Howard Minkoff); Washington DC Metropolitan Consortium (Mary Young); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Los Angeles County/Southern California Consortium (Alexandra Levine); Chicago Consortium (Mardge Cohen); and Data Analysis Center (Stephen Gange). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.